[1] 张成. Duchenne型肌营养不良治疗的研究进展[J]. 中国现代神经疾病杂志, 2007, 7(2): 120-125.
[2] Mayhew AG, Cano SJ, Scott E, et al. Detecting meaningful change using the North Star Ambulatory Assessment in Duchenne muscular dystrophy [J]. Dev Med Child Neurol, 2013, 55(11): 1046-1052.
[3] Raman SV, Cripe LH. Glucocorticoid Therapy for Duchenne Cardiomyopathy: A Hobson's Choice? [J]. J Am Heart Assoc, 2015, 4(4): 1896.
[4] Townsend EL, Tamhane H, Gross KD. Effects of AFO use on walking in boys with Duchenne muscular dystrophy: a pilot study [J]. Pediatr Phys Ther, 2015, 27(1): 51-57.
[5] de Moura MC, Wutzki HC, Voos MC, et al. Is functional dependence of Duchenne muscular dystrophy patients determinant of the quality of life and burden of their caregivers? [J]. Arq Neuropsiquiatr, 2015, 73(1): 52-57.
[6] 邱卓英,李沁燚,陈迪,等. ICF-CY理论架构、方法、分类体系及其应用[J]. 中国康复理论与实践, 2014, 20(1): 1-5.
[7] 邱卓英,陈迪. 基于ICF的残疾和康复信息标准体系及其应用研究[J]. 中国康复理论与实践, 2014, 20(6): 501-507.
[8] 邱卓英,李欣,刘冯铂,等. 基于ICF的智力残疾模式、测量方法及社会支持系统研究[J]. 中国康复理论与实践, 2016, 22(4): 373-377.
[9] Stucki G, Melvin J. 《国际功能、残疾和健康分类》:对物理和康复医学进行统一概念描述的模式[J]. 卢雯,李智玲,译. 中国康复理论与实践, 2008, 14(12): 1108-1111.
[10] 李惠,史惟,孙勇,等. 能力低下儿童评定量表功能性量表条目与儿童及青少年版国际功能、残疾和健康分类类目的关联分析[J]. 中国康复医学杂志, 2014, 29(6): 521-527.
[11] 史惟,朱默,翟淳,等. 基于ICF-CY的脑瘫粗大运动功能测试量表内容效度分析[J]. 中国康复理论与实践, 2013, 19(1): 13-18.
[12] 史惟,李惠,苏怡,等. 定量等长肌力测定在Duchenne型和Becker型肌营养不良症患儿下肢肌力测定中的信度评价[J]. 中国现代神经疾病杂志, 2015, 15(5): 387-392.
[13] Smith J, Eagle M, Scott E, et al. Body mass index (BMI) and growth in Duchenne Muscular Dystrophy (DMD) [J]. Neuromuscul Disord, 2011, 21(9): 651-652.
[14] 史惟. Duchenne型肌营养不良症运动功能评价及其临床应用研究进展[J]. 中国现代神经疾病杂志, 2015, 15(6): 426-431.
[15] Elena M, Diego M, Angela B, et al. North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy [J]. Neuromuscul Disord, 2010, 20(11): 712-716.
[16] 秦伦,黄真. 假肥大性肌营养不良症运动功能评定新进展[J]. 中华物理医学与康复杂志, 2015, 37(3): 235-238.
[17] Fernandes LA, Caromano FA, Assis SM, et al. Relationship between the climbing up and climbing down stairs domain scores on the FES-DMD, the score on the Vignos Scale, age and timed performance of functional activities in boys with Duchenne muscular dystrophy [J]. Braz J Phys Ther, 2014, 18(6): 513-520.
[18] Noviello M, Tedesco FS, Bondanza A, et al. Inflammation converts human mesoangioblasts into targets of alloreactive immune responses: implications for allogeneic cell therapy of DMD [J]. Mol Ther, 2014, 22(7): 1342-1352.
[19] Mazzone E, Vasco G, Sormani MP, et al. Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study [J]. Neurology, 2011, 77(3): 250-256.
[20] Mendell JR, Rodino-Klapac L, Sahenk Z, et al. Eteplirsen in Duchenne Muscular Dystrophy (DMD): 3 year update on Six-Minute Walk Test (6MWT) and Safety [J]. Neuromuscul Disord, 2014, 24(9-10): 922.
[21] Connolly AM, Florence JM, Cradock MM, et al. Motor and cognitive assessment of infants and young boys with Duchenne Muscular Dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network [J]. Neuromuscul Disord, 2013, 23(7): 529-539. |